Literature DB >> 1730510

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).

R Larsson1, J Kristensen, C Sandberg, P Nygren.   

Abstract

An automated fluorometric microculture cytotoxicity assay (FMCA) based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein diacetate (FDA) to fluorescein was employed for chemotherapeutic-drug-sensitivity testing of tumor-cell suspensions from patients with leukemia. Fluorescence was linearly related to cell number, and reproducible measurements of drug sensitivity could be performed using fresh or cryopreserved leukemia cells. A marked heterogeneity with respect to chemotherapeutic drug sensitivity was observed for a panel of cytotoxic drugs tested in 43 samples from 35 patients with treated or untreated acute and chronic leukemia. For samples obtained from patients with chronic lymphocytic and acute myelocytic leukemia, sensitivity profiles for standard drugs corresponded to known clinical activity and the assay detected primary and acquired drug resistance. Individual in vitro/in vivo correlations indicated high specificity with respect to the identification of drug resistance. The results suggest that the FMCA may be a simple and rapid method for in vivo-representative determinations of chemotherapeutic drug resistance in tumor cells obtained from patients with leukemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730510     DOI: 10.1002/ijc.2910500204

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Topoisomerase II-mediated alterations of K562 drug resistant sublines.

Authors:  R Zhou; Y Wang; A Gruber; R Larsson; E Castaños-Vèlez; E Liliemark
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 2.  Search for bioactive natural products from medicinal plants of Bangladesh.

Authors:  Firoj Ahmed; Samir Kumar Sadhu; Masami Ishibashi
Journal:  J Nat Med       Date:  2010-07-06       Impact factor: 2.343

3.  2-methoxy-1,4-naphthoquinone isolated from Impatiens balsamina in a screening program for activity to inhibit Wnt signaling.

Authors:  Naomi Mori; Kazufumi Toume; Midori A Arai; Takashi Koyano; Thaworn Kowithayakorn; Masami Ishibashi
Journal:  J Nat Med       Date:  2010-10-01       Impact factor: 2.343

4.  Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Authors:  Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

5.  Acoschimperoside P, 2'-acetate: a Hedgehog signaling inhibitory constituent from Vallaris glabra.

Authors:  Yusnita Rifai; Midori A Arai; Takashi Koyano; Thaworn Kowithayakorn; Masami Ishibashi
Journal:  J Nat Med       Date:  2011-04-06       Impact factor: 2.343

Review 6.  In vitro assays for the evaluation of drug resistance in tumor cells.

Authors:  Jozef Hatok; Eva Babusikova; Tatiana Matakova; Dusan Mistuna; Dusan Dobrota; Peter Racay
Journal:  Clin Exp Med       Date:  2008-09-26       Impact factor: 3.984

7.  Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Authors:  Henrik Lövborg; Robert Burman; Joachim Gullbo
Journal:  BMC Res Notes       Date:  2009-06-29

8.  DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.

Authors:  Florian T Unger; Hermann A Klasen; Garri Tchartchian; Rudy L de Wilde; Irene Witte
Journal:  BMC Cancer       Date:  2009-10-10       Impact factor: 4.430

Review 9.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03

10.  The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.

Authors:  M Sandström; M Johansson; U Andersson; A Bergh; A T Bergenheim; R Henriksson
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.